Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents

Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells

(2014) Jurate Savickiene et al.   ANTI-CANCER DRUGS

Combined autophagy and HDAC inhibition

(2014) Devalingam Mahalingam et al.   Autophagy

Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells

(2014) Selvaraju Karthik et al.   BIOMEDICINE & PHARMACOTHERAPY

Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors

(2014) Toshihiko Tashima et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers

(2014) Jennifer J. Wheler et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Spiruchostatin A and B, novel histone deacetylase inhibitors, induce apoptosis through reactive oxygen species-mitochondria pathway in human lymphoma U937 cells

(2014) Mati Ur Rehman et al.   CHEMICO-BIOLOGICAL INTERACTIONS

A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study

(2014) A. Thomas et al.   CLINICAL CANCER RESEARCH

Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors

(2014) T. Shimizu et al.   CLINICAL CANCER RESEARCH

A Structural Insight into Hydroxamic Acid Based Histone Deacetylase Inhibitors for the Presence of Anticancer Activity

(2014) H. Rajak et al.   CURRENT MEDICINAL CHEMISTRY

Belinostat: First Global Approval

(2014) Raewyn M. Poole   DRUGS

Sirtuin inhibitors as anticancer agents

(2014) Jing Hu et al.   Future Medicinal Chemistry

Energy-optimised pharmacophore approach to identify potential hotspots during inhibition of Class II HDAC isoforms

(2014) Shabir Ahmad Ganai et al.   JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS

Modification and Biological Evaluation of Thiazole Derivatives as Novel Inhibitors of Metastatic Cancer Cell Migration and Invasion

(2014) Shilong Zheng et al.   JOURNAL OF MEDICINAL CHEMISTRY

Novel Colchicine-Site Binders with a Cyclohexanedione Scaffold Identified through a Ligand-Based Virtual Screening Approach

(2014) María-Dolores Canela et al.   JOURNAL OF MEDICINAL CHEMISTRY

A Potent HDAC Inhibitor, 1-Alaninechlamydocin, from a Tolypocladium sp. Induces G2/M Cell Cycle Arrest and Apoptosis in MIA PaCa-2 Cells

(2014) Lin Du et al.   JOURNAL OF NATURAL PRODUCTS

Vorinostat as a radiosensitizer for brain metastasis: a phase I clinical trial

(2014) Wenyin Shi et al.   JOURNAL OF NEURO-ONCOLOGY

The novel histone deacetylase inhibitor thailandepsin A inhibits anaplastic thyroid cancer growth

(2014) Eric Weinlander et al.   JOURNAL OF SURGICAL RESEARCH

Anticancer Agents Targeted to Sirtuins

(2014) Tomohiro Kozako et al.   MOLECULES

Treatment of Nasopharyngeal Carcinoma Cells with the Histone-Deacetylase Inhibitor Abexinostat: Cooperative Effects with Cis-platin and Radiotherapy on Patient-Derived Xenografts

(2014) Mélanie Gressette et al.   PLoS One

A Phase I Protocol of Hydralazine and Valproic Acid in Advanced, Previously Treated Solid Cancers

(2014) Julie Bauman et al.   Translational Oncology

Modulation of Activity Profiles for Largazole-Based HDAC Inhibitors through Alteration of Prodrug Properties

(2014) Lilibeth A. Salvador et al.   ACS Medicinal Chemistry Letters

Thioester derivatives of the natural product psammaplin A as potent histone deacetylase inhibitors

(2013) Matthias G J Baud et al.   Beilstein Journal of Organic Chemistry

Lactam based 7-amino suberoylamide hydroxamic acids as potent HDAC inhibitors

(2013) Maurizio Taddei et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF)

(2013) John Mascarenhas et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma

(2013) Yasuhiro Oki et al.   BRITISH JOURNAL OF HAEMATOLOGY

A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy

(2013) Guido Finazzi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Discovery of Potent HDAC Inhibitors Based on Chlamydocin with Inhibitory Effects on Cell Migration

(2013) Shimiao Wang et al.   ChemMedChem

The Effect of Various Zinc Binding Groups on Inhibition of Histone Deacetylases 1-11

(2013) Andreas S. Madsen et al.   ChemMedChem

First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors

(2013) A. T. Brunetto et al.   CLINICAL CANCER RESEARCH

Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers

(2013) L. Amiri-Kordestani et al.   CLINICAL CANCER RESEARCH

Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I

(2013) Sylvain Fouliard et al.   EUROPEAN JOURNAL OF CANCER

Novel toll-like receptor 4 (TLR4) antagonists identified by structure- and ligand-based virtual screening

(2013) Urban Švajger et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability

(2013) Benjamin E. L. Lauffer et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor

(2013) Denise A. Yardley et al.   JOURNAL OF CLINICAL ONCOLOGY

Ligand release mechanisms and channels in histone deacetylases

(2013) Subha Kalyaanamoorthy et al.   JOURNAL OF COMPUTATIONAL CHEMISTRY

Synthesis and Structure–Activity Relationship of 3-Hydroxypyridine-2-thione-Based Histone Deacetylase Inhibitors

(2013) Quaovi H. Sodji et al.   JOURNAL OF MEDICINAL CHEMISTRY

Total Synthesis and Full Histone Deacetylase Inhibitory Profiling of Azumamides A–E as Well as β2- epi-Azumamide E and β3-epi-Azumamide E

(2013) Jesper S. Villadsen et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of the First Histone Deacetylase 6/8 Dual Inhibitors

(2013) David E. Olson et al.   JOURNAL OF MEDICINAL CHEMISTRY

A Phase II Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Pretreated Patients with Small-Cell Lung Cancer

(2013) Filippo de Marinis et al.   Journal of Thoracic Oncology

Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients

(2013) U Platzbecker et al.   LEUKEMIA

A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study

(2013) Mark H. Kirschbaum et al.   LEUKEMIA & LYMPHOMA

Comparing Histone Deacetylase Inhibitor Responses in Genetically Engineered Mouse Lung Cancer Models and a Window of Opportunity Trial in Patients with Lung Cancer

(2013) T. Ma et al.   MOLECULAR CANCER THERAPEUTICS

Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group

(2013) Mercedes Lobera et al.   Nature Chemical Biology

A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium

(2013) Alexandra P. Zorzi et al.   PEDIATRIC BLOOD & CANCER

Vorinostat Induces Apoptosis and Differentiation in Myeloid Malignancies: Genetic and Molecular Mechanisms

(2013) Gabriela Silva et al.   PLoS One

Resveratrol as a Pan-HDAC Inhibitor Alters the Acetylation Status of Jistone Proteins in Human-Derived Hepatoblastoma Cells

(2013) Sascha Venturelli et al.   PLoS One

HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses

(2013) J E Bolden et al.   Cell Death & Disease

Discovery of a Series of Thiazole Derivatives as Novel Inhibitors of Metastatic Cancer Cell Migration and Invasion

(2013) Shilong Zheng et al.   ACS Medicinal Chemistry Letters

Structural Basis for the Inhibition of Histone Deacetylase 8 (HDAC8), a Key Epigenetic Player in the Blood Fluke Schistosoma mansoni

(2013) Martin Marek et al.   PLoS Pathogens

Energy based pharmacophore mapping of HDAC inhibitors against class I HDAC enzymes

(2012) Subha Kalyaanamoorthy et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors: Part II

(2012) Chulho Lee et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Structure-Activity Relationship of Novel Lactam Based Histone Deacetylase Inhibitors as Potential Anticancer Drugs

(2012) Jee-Sun Yang et al.   BULLETIN OF THE KOREAN CHEMICAL SOCIETY

Phase I study of 5-aza-2′-deoxycytidine in combination with valproic acid in non-small-cell lung cancer

(2012) B. F. Chu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase 1 Results From a Study of Romidepsin in Combination With Gemcitabine in Patients With Advanced Solid Tumors

(2012) Suzanne F. Jones et al.   CANCER INVESTIGATION

Discovery and Mechanism of Natural Products as Modulators of Histone Acetylation

(2012) Lilibeth A. Salvador et al.   CURRENT DRUG TARGETS

590 Final Results of a Phase Ib Study of CUDC-101, a Multitargeted Inhibitor of EGFR, HER2, and HDAC, in Patients with Advanced Head and Neck, Gastric, Breast, Liver, and Non-small Cell Lung Cancer

(2012) M. Voi et al.   EUROPEAN JOURNAL OF CANCER

Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2V617F myeloproliferative neoplasm patients

(2012) Ariel Amaru Calzada et al.   EXPERIMENTAL HEMATOLOGY

A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study

(2012) Don S. Dizon et al.   GYNECOLOGIC ONCOLOGY

Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial

(2012) Toshihiko Doi et al.   International Journal of Clinical Oncology

Phase II Activity of Belinostat (PXD-101), Carboplatin, and Paclitaxel in Women With Previously Treated Ovarian Cancer

(2012) Don S. Dizon et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors

(2012) Akira Fukutomi et al.   INVESTIGATIONAL NEW DRUGS

Molecular Dynamics Simulation Study Explaining Inhibitor Selectivity in Different Class of Histone Deacetylases

(2012) Sundarapandian Thangapandian et al.   JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS

Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy

(2012) Samir E. Witta et al.   JOURNAL OF CLINICAL ONCOLOGY

Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

(2012) Bertrand Coiffier et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis

(2012) Alfonso Quintás-Cardama et al.   LEUKEMIA RESEARCH

Sirtuins as regulators of metabolism and healthspan

(2012) Riekelt H. Houtkooper et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Molecular Modeling Study on Tunnel Behavior in Different Histone Deacetylase Isoforms

(2012) Sundarapandian Thangapandian et al.   PLoS One

Class I and Class II Histone Deacetylases Are Potential Therapeutic Targets for Treating Pancreatic Cancer

(2012) Guan Wang et al.   PLoS One

Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma

(2012) Marie Saelen et al.   Radiation Oncology

Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome

(2011) Sophie Dimicoli et al.   AMERICAN JOURNAL OF HEMATOLOGY

Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)

(2011) Amanda Cashen et al.   ANNALS OF HEMATOLOGY

Synthesis and biological evaluation of piperamide analogues as HDAC inhibitors

(2011) Yu Luo et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma

(2011) D. Buglio et al.   BLOOD

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

(2011) R. L. Piekarz et al.   BLOOD

Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia

(2011) M. J. Bishton et al.   BLOOD

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours

(2011) A R A Razak et al.   BRITISH JOURNAL OF CANCER

Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours

(2011) R Pili et al.   BRITISH JOURNAL OF CANCER

A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer

(2011) M. G. Fakih et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Carbamate Prodrug Concept for Hydroxamate HDAC Inhibitors

(2011) Sonja Schlimme et al.   ChemMedChem

Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors

(2011) Sachi Morita et al.   INVESTIGATIONAL NEW DRUGS

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination

(2011) Michael Millward et al.   INVESTIGATIONAL NEW DRUGS

Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors

(2011) Giuseppe Giaccone et al.   JOURNAL OF CLINICAL ONCOLOGY

Design, Synthesis, Docking, and Biological Evaluation of Novel Diazide-Containing Isoxazole- and Pyrazole-Based Histone Deacetylase Probes

(2011) Raghupathi Neelarapu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Exploration of the valproic acid binding site on histone deacetylase 8 using docking and molecular dynamic simulations

(2011) Jorge Antonio Bermúdez-Lugo et al.   JOURNAL OF MOLECULAR MODELING

Suppression of Histone Deacetylase 11 Promotes Expression of IL-10 in Kupffer Cells and Induces Tolerance Following Orthotopic Liver Transplantation in Rats

(2011) Zheng-rong Lian et al.   JOURNAL OF SURGICAL RESEARCH

The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations

(2011) David J Bonda et al.   LANCET NEUROLOGY

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial

(2011) Anas Younes et al.   LANCET ONCOLOGY

Unknown

(2011) Antonio Furlan et al.   MOLECULAR MEDICINE

A Pilot Phase II Study of Valproic Acid for Treatment of Low-Grade Neuroendocrine Carcinoma

(2011) T. A. Mohammed et al.   ONCOLOGIST

The Mechanism of Action of the Histone Deacetylase Inhibitor Vorinostat Involves Interaction with the Insulin-Like Growth Factor Signaling Pathway

(2011) Rive Sarfstein et al.   PLoS One

Design, synthesis and biological evaluation of novel histone deacetylase inhibitors based on virtual screening

(2011) Hui Lu et al.   Acta Pharmaceutica Sinica B

On the inhibition of histone deacetylase 8

(2010) Guillermina Estiu et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors

(2010) Eunhyun Choi et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells

(2010) Sonja Mandl-Weber et al.   BRITISH JOURNAL OF HAEMATOLOGY

A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy

(2010) Peter M. Wilson et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity

(2010) Cheng-Jung Lai et al.   CANCER RESEARCH

A Structure-Based Virtual Screening Approach toward the Discovery of Histone Deacetylase Inhibitors: Identification of Promising Zinc-Chelating Groups

(2010) Hwangseo Park et al.   ChemMedChem

Phase 1 Study of Valproic Acid in Pediatric Patients with Refractory Solid or CNS Tumors: A Children's Oncology Group Report

(2010) J. M. Su et al.   CLINICAL CANCER RESEARCH

A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Two Schedules of Vorinostat in Combination with 5-Fluorouracil and Leucovorin in Patients with Refractory Solid Tumors

(2010) M. G. Fakih et al.   CLINICAL CANCER RESEARCH

Vorinostat Plus Bortezomib for the Treatment of Relapsed/Refractory Multiple Myeloma: A Case Series Illustrating Utility in Clinical Practice

(2010) Amitabha Mazumder et al.   Clinical Lymphoma Myeloma & Leukemia

Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours

(2010) Helen J. Mackay et al.   EUROPEAN JOURNAL OF CANCER

Nonhistone protein acetylation as cancer therapy targets

(2010) Brahma N Singh et al.   Expert Review of Anticancer Therapy

Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

(2010) Sean J. Whittaker et al.   JOURNAL OF CLINICAL ONCOLOGY

Docking-enabled pharmacophore model for histone deacetylase 8 inhibitors and its application in anti-cancer drug discovery

(2010) Thangapandian Sundarapandian et al.   JOURNAL OF MOLECULAR GRAPHICS & MODELLING

Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma

(2010) Suresh S. Ramalingam et al.   Journal of Thoracic Oncology

Discovery of a novel histone deacetylase 8 inhibitor by virtual screening

(2010) Lei Zhang et al.   MEDICINAL CHEMISTRY RESEARCH

Histone deacetylase inhibitors (HDACIs). Structure-activity relationships: history and new QSAR perspectives

(2010) Eleni Pontiki et al.   MEDICINAL RESEARCH REVIEWS

Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair

(2010) J.- H. Lee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma

(2009) Monica Galli et al.   ANNALS OF HEMATOLOGY

Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia

(2009) Kristie A. Blum et al.   BRITISH JOURNAL OF HAEMATOLOGY

Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma

(2009) G. Lopez et al.   CLINICAL CANCER RESEARCH

NAD+, Sirtuins, and Cardiovascular Disease

(2009) Nica Borradaile et al.   CURRENT PHARMACEUTICAL DESIGN

The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines

(2009) Brigette B.Y. Ma et al.   INVESTIGATIONAL NEW DRUGS

Acetylation/Deacetylation Modulates the Stability of DNA Replication Licensing Factor Cdt1

(2009) Michele A. Glozak et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Histone Deacetylase Inhibitors in Cancer Therapy

(2009) Andrew A. Lane et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

(2009) Richard L. Piekarz et al.   JOURNAL OF CLINICAL ONCOLOGY

Dietary Sulforaphane, a Histone Deacetylase Inhibitor for Cancer Prevention

(2009) Emily Ho et al.   JOURNAL OF NUTRITION

Butyrate and propionate induced activated or non-activated neutrophil apoptosis via HDAC inhibitor activity but without activating GPR-41/GPR-43 pathways

(2009) Michiko Aoyama et al.   NUTRITION

Molecular modeling studies toward the structural optimization of new cyclopeptide-based HDAC inhibitors modeled on the natural product FR235222

(2008) Simone Di Micco et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Synthesis and structure–activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group

(2008) Po C. Chen et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Identification of KD5170: A novel mercaptoketone-based histone deacetylase inhibitor

(2008) Joseph E. Payne et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

(2008) G. Garcia-Manero et al.   BLOOD

Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances Sp3 binding on the P21WAF1 promoter

(2008) H. Nian et al.   CARCINOGENESIS

A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas

(2008) L. Gore et al.   CLINICAL CANCER RESEARCH

Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin

(2008) D. S. Schrump et al.   CLINICAL CANCER RESEARCH

Effects of FR235222, a novel HDAC inhibitor, in proliferation and apoptosis of human leukaemia cell lines: Role of Annexin A1

(2008) Antonello Petrella et al.   EUROPEAN JOURNAL OF CANCER

Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors

(2008) Lillian L. Siu et al.   JOURNAL OF CLINICAL ONCOLOGY

Syntheses and Biological Activity of Amamistatin B and Analogs

(2008) Kelley A. Fennell et al.   JOURNAL OF ORGANIC CHEMISTRY

Structure and Activity of Largazole, a Potent Antiproliferative Agent from the Floridian Marine CyanobacteriumSymplocasp.

(2008) Kanchan Taori et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo

(2008) C. A. Hassig et al.   MOLECULAR CANCER THERAPEUTICS

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

(2008) M. Fournel et al.   MOLECULAR CANCER THERAPEUTICS

The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance

(2008) Alejandro Villagra et al.   NATURE IMMUNOLOGY